{"protocolSection":{"identificationModule":{"nctId":"NCT00560417","orgStudyIdInfo":{"id":"11647"},"secondaryIdInfos":[{"id":"F3Z-US-IOPB","type":"OTHER","domain":"Eli Lilly and Company"}],"organization":{"fullName":"Eli Lilly and Company","class":"INDUSTRY"},"briefTitle":"Comparison of Two Basal Insulins for Patients With Type 2 Diabetes Taking Oral Diabetes Medicines and Exenatide","officialTitle":"A Randomized Trial Comparing Insulin Lispro Protamine Suspension With Insulin Glargine in Subjects With Type 2 Diabetes on Oral Antihyperglycemic Medications and Exenatide"},"statusModule":{"statusVerifiedDate":"2011-01","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2007-11"},"primaryCompletionDateStruct":{"date":"2009-12","type":"ACTUAL"},"completionDateStruct":{"date":"2009-12","type":"ACTUAL"},"studyFirstSubmitDate":"2007-11-15","studyFirstSubmitQcDate":"2007-11-15","studyFirstPostDateStruct":{"date":"2007-11-19","type":"ESTIMATED"},"resultsFirstSubmitDate":"2010-11-12","resultsFirstSubmitQcDate":"2010-11-12","resultsFirstPostDateStruct":{"date":"2010-12-14","type":"ESTIMATED"},"lastUpdateSubmitDate":"2011-01-12","lastUpdatePostDateStruct":{"date":"2011-01-13","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"oldNameTitle":"Chief Medical Officer","oldOrganization":"Eli Lilly"},"leadSponsor":{"name":"Eli Lilly and Company","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false},"descriptionModule":{"briefSummary":"This study will compare insulin lispro protamine suspension (ILPS) and insulin glargine in combination with the patient's oral diabetes medications and exenatide, for their ability to control blood sugar in patients with type 2 diabetes."},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":339,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"ILPS","type":"ACTIVE_COMPARATOR","description":"Insulin Lispro Protamine Suspension (ILPS)","interventionNames":["Drug: Insulin Lispro Protamine Suspension"]},{"label":"Glargine","type":"ACTIVE_COMPARATOR","description":"Insulin Glargine","interventionNames":["Drug: Insulin Glargine"]}],"interventions":[{"type":"DRUG","name":"Insulin Lispro Protamine Suspension","description":"Administered subcutaneously once a day at bedtime","armGroupLabels":["ILPS"],"otherNames":["LY275585[P]"]},{"type":"DRUG","name":"Insulin Glargine","description":"Administered subcutaneously once a day at bedtime","armGroupLabels":["Glargine"],"otherNames":["Lantus"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Change From Baseline in Hemoglobin A1C (HbA1c) at Endpoint (Last Observation Carried Forward [LOCF])","description":"Least squares mean values were controlled for Baseline + Baseline HbA1c Group + Baseline sulfonylurea (SU) Group.","timeFrame":"Baseline, Endpoint (LOCF) up to 24 weeks"}],"secondaryOutcomes":[{"measure":"Actual Hemoglobin A1C at 24 Weeks and Endpoint (LOCF)","description":"Least squares mean values were controlled for Baseline + Baseline HbA1c Group + Baseline SU Group.","timeFrame":"24 weeks, Endpoint (LOCF) up to 24 weeks"},{"measure":"Change From Baseline in Hemoglobin A1C at 24 Weeks and Endpoint (LOCF)","description":"Least squares mean values were controlled for Baseline + Baseline HbA1c Group + Baseline SU Group.","timeFrame":"Baseline, 24 Weeks, Endpoint (LOCF) up to 24 weeks"},{"measure":"Percentage of Participants With Hemoglobin A1C Less Than 7.0% and Hemoglobin A1C Less Than or Equal to 6.5%","timeFrame":"Weeks 12, 18, 24 and Endpoint (LOCF) up to 24 weeks"},{"measure":"7-Point Self-Monitored Blood Glucose (SMBG) Profiles at Baseline and Endpoint (LOCF)","description":"SMBG at morning pre-meal, morning post-prandial, midday pre-meal, midday post-prandial, evening pre-meal, evening postprandial, 0300 hours. Post-prandial glucose is measured 2 hours after the start of the meal.","timeFrame":"Baseline, Endpoint (LOCF) up to 24 weeks"},{"measure":"Glycemic Variability at Baseline and Endpoint (LOCF)","description":"Glycemic variability was defined as the standard deviation (SD) of a participant's intra-day 7-point, self-monitored, blood glucose. Mean SD was calculated based on the SD for each participant in the study.","timeFrame":"Baseline, Endpoint (LOCF) up to 24 weeks"},{"measure":"Incidence of Self-reported Hypoglycemic Episodes (All, Non-Nocturnal, Nocturnal, and Severe)","description":"Overall:any time after randomization.Episode:any time patient experienced sign/symptom associated with hypoglycemia, or had blood glucose level ≤70 mg/dL. Non-nocturnal:any episode that occurred between waking and bedtime. Nocturnal:any episode that occurred between bedtime and waking.Severe:episode with symptoms consistent with neuroglycopenia in which patient requires assistance,and is associated with:blood glucose value \\<50 mg/dL or prompt recovery after oral carbohydrate, glucagon, or intravenous glucose.Incidence(%)=(Number of patients experiencing episodes/number of patients in arm)\\*100.","timeFrame":"Baseline to Endpoint (LOCF) up to 24 weeks"},{"measure":"Rate of All, Non-Nocturnal, and Nocturnal Self-Reported Hypoglycemic Episodes (Adjusted for One Year)","description":"Rate of self-reported hypoglycemic episodes, all, non-nocturnal, and nocturnal, at Endpoint (LOCF) and overall. Rate is reported as episodes/participant/365 days. Episode = any time participant feels that he/she is experiencing a sign or symptom that is associated with hypoglycemia or has a blood glucose level of ≤70 mg/dL, even if it was not associated with signs, symptoms, or treatment. Overall=any time during the post-randomization visits within the study period. Nocturnal=Any episode that occurs between bedtime and waking. Non-Nocturnal=Any episode that occurs between waking and bedtime.","timeFrame":"Baseline to Endpoint (LOCF) up to 24 weeks"},{"measure":"Actual Body Weight at Baseline and Endpoint (LOCF)","timeFrame":"Baseline, Endpoint (LOCF) up to 24 weeks"},{"measure":"Change From Baseline in Body Weight at Endpoint (LOCF)","timeFrame":"Baseline, Endpoint (LOCF) up to 24 weeks"},{"measure":"Total Daily Insulin Dose at Endpoint (LOCF)","timeFrame":"Endpoint (LOCF) up to 24 weeks"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Must have type 2 diabetes\n* Must be at least 18 years of age and less than 75 years of age\n* Must be taking exenatide 10 micrograms twice a day (BID) for at least 3 months\n* Must be taking one of the following oral diabetes medication regimens for at least 3 months: (1) metformin (2) metformin + sulfonylurea (3) metformin + thiazolidinedione (TZD). Doses must be at or above the following: Metformin--1500 mg/day, Sulfonylurea--1/2 the maximum daily dose according to the product label, TZD--30 mg/day pioglitazone\n* Must have a hemoglobin A1C greater than or equal to 7.0% and less than or equal to 10.0%\n\nExclusion Criteria:\n\n* Must not have used insulin on a regular basis during the past 2 years\n* Must not have taken any glucose-lowering medications not included in the inclusion criteria in the past 3 months\n* Must not have had more than one episode of severe hypoglycemia in the past 6 months\n* Must not have clinically significant hematologic, oncologic, renal, cardiac, hepatic, or gastrointestinal disease\n* Must not be pregnant or intend to get pregnant during the course of the study","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"74 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)","affiliation":"Eli Lilly and Company","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Phoenix","state":"Arizona","zip":"85028","country":"United States","geoPoint":{"lat":33.44838,"lon":-112.07404}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Concord","state":"California","zip":"94520","country":"United States","geoPoint":{"lat":37.97798,"lon":-122.03107}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Escondido","state":"California","zip":"92026","country":"United States","geoPoint":{"lat":33.11921,"lon":-117.08642}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Fresno","state":"California","zip":"93720","country":"United States","geoPoint":{"lat":36.74773,"lon":-119.77237}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Modesto","state":"California","zip":"95355","country":"United States","geoPoint":{"lat":37.6391,"lon":-120.99688}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Orange","state":"California","zip":"92869","country":"United States","geoPoint":{"lat":33.78779,"lon":-117.85311}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Inverness","state":"Florida","zip":"34452","country":"United States","geoPoint":{"lat":28.83582,"lon":-82.33037}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Jacksonville","state":"Florida","zip":"32204","country":"United States","geoPoint":{"lat":30.33218,"lon":-81.65565}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Lake Worth","state":"Florida","zip":"33461","country":"United States","geoPoint":{"lat":26.61708,"lon":-80.07231}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Miami","state":"Florida","zip":"33183","country":"United States","geoPoint":{"lat":25.77427,"lon":-80.19366}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Orlando","state":"Florida","zip":"32804","country":"United States","geoPoint":{"lat":28.53834,"lon":-81.37924}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Palm Harbor","state":"Florida","zip":"34684","country":"United States","geoPoint":{"lat":28.07807,"lon":-82.76371}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Pembroke Pines","state":"Florida","zip":"33029","country":"United States","geoPoint":{"lat":26.00315,"lon":-80.22394}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Plantation","state":"Florida","zip":"33324","country":"United States","geoPoint":{"lat":26.13421,"lon":-80.23184}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"West Palm Beach","state":"Florida","zip":"33401","country":"United States","geoPoint":{"lat":26.71534,"lon":-80.05337}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Honolulu","state":"Hawaii","zip":"96813","country":"United States","geoPoint":{"lat":21.30694,"lon":-157.85833}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Idaho Falls","state":"Idaho","zip":"83404","country":"United States","geoPoint":{"lat":43.46658,"lon":-112.03414}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Avon","state":"Indiana","zip":"46123","country":"United States","geoPoint":{"lat":39.76282,"lon":-86.39972}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Bloomington","state":"Indiana","zip":"47403","country":"United States","geoPoint":{"lat":39.16533,"lon":-86.52639}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"South Bend","state":"Indiana","zip":"46617","country":"United States","geoPoint":{"lat":41.68338,"lon":-86.25001}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Des Moines","state":"Iowa","zip":"50314","country":"United States","geoPoint":{"lat":41.60054,"lon":-93.60911}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Lexington","state":"Kentucky","zip":"40503","country":"United States","geoPoint":{"lat":37.98869,"lon":-84.47772}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Baton Rouge","state":"Louisiana","zip":"70808","country":"United States","geoPoint":{"lat":30.44332,"lon":-91.18747}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Lafayette","state":"Louisiana","zip":"70503","country":"United States","geoPoint":{"lat":30.22409,"lon":-92.01984}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Metairie","state":"Louisiana","zip":"70006","country":"United States","geoPoint":{"lat":29.98409,"lon":-90.15285}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Biddeford","state":"Maine","zip":"04005","country":"United States","geoPoint":{"lat":43.49258,"lon":-70.45338}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Chesterfield","state":"Missouri","zip":"63017","country":"United States","geoPoint":{"lat":38.66311,"lon":-90.57707}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Jefferson City","state":"Missouri","zip":"65109","country":"United States","geoPoint":{"lat":38.5767,"lon":-92.17352}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"St Louis","state":"Missouri","zip":"63104","country":"United States","geoPoint":{"lat":38.62727,"lon":-90.19789}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Omaha","state":"Nebraska","zip":"68131","country":"United States","geoPoint":{"lat":41.25626,"lon":-95.94043}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Las Vegas","state":"Nevada","zip":"89148","country":"United States","geoPoint":{"lat":36.17497,"lon":-115.13722}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Nashua","state":"New Hampshire","zip":"03063","country":"United States","geoPoint":{"lat":42.76537,"lon":-71.46757}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Rochester","state":"New York","zip":"14607","country":"United States","geoPoint":{"lat":43.15478,"lon":-77.61556}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Syracuse","state":"New York","zip":"13210","country":"United States","geoPoint":{"lat":43.04812,"lon":-76.14742}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Morehead City","state":"North Carolina","zip":"28557","country":"United States","geoPoint":{"lat":34.72294,"lon":-76.72604}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"London","state":"Ohio","zip":"43140","country":"United States","geoPoint":{"lat":39.88645,"lon":-83.44825}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Mason","state":"Ohio","zip":"45040","country":"United States","geoPoint":{"lat":39.36006,"lon":-84.30994}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Toledo","state":"Ohio","zip":"43606","country":"United States","geoPoint":{"lat":41.66394,"lon":-83.55521}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Greer","state":"South Carolina","zip":"29651","country":"United States","geoPoint":{"lat":34.93873,"lon":-82.22706}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Myrtle Beach","state":"South Carolina","zip":"29572","country":"United States","geoPoint":{"lat":33.68906,"lon":-78.88669}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Kingsport","state":"Tennessee","zip":"37660","country":"United States","geoPoint":{"lat":36.54843,"lon":-82.56182}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Memphis","state":"Tennessee","zip":"38119","country":"United States","geoPoint":{"lat":35.14953,"lon":-90.04898}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Austin","state":"Texas","zip":"78731","country":"United States","geoPoint":{"lat":30.26715,"lon":-97.74306}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Dallas","state":"Texas","zip":"75231","country":"United States","geoPoint":{"lat":32.78306,"lon":-96.80667}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"San Antonio","state":"Texas","zip":"78229","country":"United States","geoPoint":{"lat":29.42412,"lon":-98.49363}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"South Burlington","state":"Vermont","zip":"05403","country":"United States","geoPoint":{"lat":44.46699,"lon":-73.17096}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Virginia Beach","state":"Virginia","zip":"23462","country":"United States","geoPoint":{"lat":36.85293,"lon":-75.97799}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Spokane","state":"Washington","zip":"99202","country":"United States","geoPoint":{"lat":47.65966,"lon":-117.42908}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Vancouver","state":"Washington","zip":"98664","country":"United States","geoPoint":{"lat":45.63873,"lon":-122.66149}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Ponce","zip":"00731","country":"Puerto Rico","geoPoint":{"lat":18.01031,"lon":-66.62398}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Toa Baja","zip":"00949","country":"Puerto Rico","geoPoint":{"lat":18.44384,"lon":-66.25961}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Yabucoa","zip":"00767","country":"Puerto Rico","geoPoint":{"lat":18.05052,"lon":-65.87933}}]}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"Intention to Treat (ITT) Population consisted of all randomized participants who received at least one dose of study drug and had at least one post-baseline measurement.","groups":[{"id":"FG000","title":"ILPS","description":"Insulin Lispro Protamine Suspension (ILPS) administered subcutaneously once a day at bedtime for 24 weeks"},{"id":"FG001","title":"Glargine","description":"Insulin Glargine administered subcutaneously once a day at bedtime for 24 weeks"}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"171"},{"groupId":"FG001","numSubjects":"168"}]},{"type":"Intention to Treat (ITT) Population","achievements":[{"groupId":"FG000","numSubjects":"170"},{"groupId":"FG001","numSubjects":"167"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"154"},{"groupId":"FG001","numSubjects":"151"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"17"},{"groupId":"FG001","numSubjects":"17"}]}],"dropWithdraws":[{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"2"}]},{"type":"Entry Criteria Not Met","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"}]},{"type":"Physician Decision","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"6"}]},{"type":"Protocol Violation","reasons":[{"groupId":"FG000","numSubjects":"6"},{"groupId":"FG001","numSubjects":"5"}]},{"type":"Sponsor Decision","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"3"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"ILPS","description":"Insulin Lispro Protamine Suspension (ILPS) administered subcutaneously once a day at bedtime for 24 weeks"},{"id":"BG001","title":"Glargine","description":"Insulin Glargine administered subcutaneously once a day at bedtime for 24 weeks"},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"171"},{"groupId":"BG001","value":"168"},{"groupId":"BG002","value":"339"}]}],"measures":[{"title":"Age Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"56.51","spread":"9.73"},{"groupId":"BG001","value":"56.24","spread":"9.33"},{"groupId":"BG002","value":"56.38","spread":"9.52"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"95"},{"groupId":"BG001","value":"75"},{"groupId":"BG002","value":"170"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"76"},{"groupId":"BG001","value":"93"},{"groupId":"BG002","value":"169"}]}]}]},{"title":"Race/Ethnicity, Customized","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"Black or African American","categories":[{"measurements":[{"groupId":"BG000","value":"13"},{"groupId":"BG001","value":"14"},{"groupId":"BG002","value":"27"}]}]},{"title":"East Asian","categories":[{"measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"11"}]}]},{"title":"Hispanic","categories":[{"measurements":[{"groupId":"BG000","value":"21"},{"groupId":"BG001","value":"17"},{"groupId":"BG002","value":"38"}]}]},{"title":"Native American","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"}]}]},{"title":"West Asian (Indian sub-continent)","categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"2"}]}]},{"title":"White","categories":[{"measurements":[{"groupId":"BG000","value":"130"},{"groupId":"BG001","value":"130"},{"groupId":"BG002","value":"260"}]}]}]},{"title":"Region of Enrollment","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"United States","categories":[{"measurements":[{"groupId":"BG000","value":"165"},{"groupId":"BG001","value":"165"},{"groupId":"BG002","value":"330"}]}]},{"title":"Puerto Rico","categories":[{"measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"9"}]}]}]},{"title":"Body Mass Index","description":"Body mass index is an estimate of body fat based on body weight divided by height squared.","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"kilograms/square meters (kg/m^2)","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"34.92","spread":"5.21"},{"groupId":"BG001","value":"34.78","spread":"5.17"},{"groupId":"BG002","value":"34.85","spread":"5.18"}]}]}]},{"title":"Body Weight","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"Kilograms","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"101.57","spread":"18.67"},{"groupId":"BG001","value":"102.33","spread":"19.73"},{"groupId":"BG002","value":"101.95","spread":"19.18"}]}]}]},{"title":"Hemoglobin A1C","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"percent of glycosylated hemoglobin","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"8.21","spread":"0.79"},{"groupId":"BG001","value":"8.22","spread":"0.80"},{"groupId":"BG002","value":"8.22","spread":"0.79"}]}]}]},{"title":"Sulfonylurea Group","description":"Participants taking a sulfonylurea at baseline.","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"Yes","categories":[{"measurements":[{"groupId":"BG000","value":"108"},{"groupId":"BG001","value":"110"},{"groupId":"BG002","value":"218"}]}]},{"title":"No","categories":[{"measurements":[{"groupId":"BG000","value":"63"},{"groupId":"BG001","value":"58"},{"groupId":"BG002","value":"121"}]}]}]},{"title":"Duration of Diabetes","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"9.51","spread":"5.98"},{"groupId":"BG001","value":"10.31","spread":"6.63"},{"groupId":"BG002","value":"9.91","spread":"6.31"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Hemoglobin A1C (HbA1c) at Endpoint (Last Observation Carried Forward [LOCF])","description":"Least squares mean values were controlled for Baseline + Baseline HbA1c Group + Baseline sulfonylurea (SU) Group.","populationDescription":"All randomized participants with at least one post-baseline measurement. Intention to Treat (ITT) population.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"percent of glycosylated hemoglobin","timeFrame":"Baseline, Endpoint (LOCF) up to 24 weeks","groups":[{"id":"OG000","title":"ILPS","description":"Insulin Lispro Protamine Suspension (ILPS) administered subcutaneously once a day at bedtime for 24 weeks"},{"id":"OG001","title":"Glargine","description":"Insulin Glargine administered subcutaneously once a day at bedtime for 24 weeks"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"170"},{"groupId":"OG001","value":"167"}]}],"classes":[{"title":"Baseline","categories":[{"measurements":[{"groupId":"OG000","value":"8.48","spread":"0.04"},{"groupId":"OG001","value":"8.47","spread":"0.04"}]}]},{"title":"Endpoint (LOCF) Change","categories":[{"measurements":[{"groupId":"OG000","value":"-1.21","spread":"0.07"},{"groupId":"OG001","value":"-1.43","spread":"0.07"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":true,"nonInferiorityType":"NON_INFERIORITY_OR_EQUIVALENCE","nonInferiorityComment":"Noninferiority margin was prespecified at 0.4%","statisticalMethod":"ANCOVA","statisticalComment":"Variable = Treatment + Baseline + Baseline HbA1c Group + Baseline SU Group.","paramType":"Mean Difference (Final Values)","paramValue":"0.22","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.06","ciUpperLimit":"0.38"}]},{"type":"SECONDARY","title":"Actual Hemoglobin A1C at 24 Weeks and Endpoint (LOCF)","description":"Least squares mean values were controlled for Baseline + Baseline HbA1c Group + Baseline SU Group.","populationDescription":"All randomized participants with at least one post-baseline measurement. Intention to Treat (ITT) population.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"percent of glycosylated hemoglobin","timeFrame":"24 weeks, Endpoint (LOCF) up to 24 weeks","groups":[{"id":"OG000","title":"ILPS","description":"Insulin Lispro Protamine Suspension (ILPS) administered subcutaneously once a day at bedtime for 24 weeks"},{"id":"OG001","title":"Glargine","description":"Insulin Glargine administered subcutaneously once a day at bedtime for 24 weeks"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"170"},{"groupId":"OG001","value":"167"}]}],"classes":[{"title":"24 weeks","categories":[{"measurements":[{"groupId":"OG000","value":"6.94","spread":"0.07"},{"groupId":"OG001","value":"6.70","spread":"0.06"}]}]},{"title":"Endpoint (LOCF)","categories":[{"measurements":[{"groupId":"OG000","value":"7.00","spread":"0.07"},{"groupId":"OG001","value":"6.78","spread":"0.07"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.003","pValueComment":"p-value is for 24 weeks.","statisticalMethod":"ANCOVA","statisticalComment":"Variable = Treatment + Baseline + Baseline HbA1c Group + Baseline SU Group","paramType":"Mean Difference (Final Values)","paramValue":"0.24","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.08","ciUpperLimit":"0.39"},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.008","pValueComment":"p-value is for Endpoint (LOCF)","statisticalMethod":"ANCOVA","statisticalComment":"Variable = Treatment + Baseline + Baseline HbA1c Group + Baseline SU Group","paramType":"Mean Difference (Final Values)","paramValue":"0.22","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.06","ciUpperLimit":"0.38"}]},{"type":"SECONDARY","title":"Change From Baseline in Hemoglobin A1C at 24 Weeks and Endpoint (LOCF)","description":"Least squares mean values were controlled for Baseline + Baseline HbA1c Group + Baseline SU Group.","populationDescription":"All randomized participants with at least one post-baseline measurement. Intention to Treat (ITT) population.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"percent of glycosylated hemoglobin","timeFrame":"Baseline, 24 Weeks, Endpoint (LOCF) up to 24 weeks","groups":[{"id":"OG000","title":"ILPS","description":"Insulin Lispro Protamine Suspension (ILPS) administered subcutaneously once a day at bedtime for 24 weeks"},{"id":"OG001","title":"Glargine","description":"Insulin Glargine administered subcutaneously once a day at bedtime for 24 weeks"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"170"},{"groupId":"OG001","value":"167"}]}],"classes":[{"title":"Baseline","categories":[{"measurements":[{"groupId":"OG000","value":"8.48","spread":"0.04"},{"groupId":"OG001","value":"8.47","spread":"0.04"}]}]},{"title":"24 Weeks Change","categories":[{"measurements":[{"groupId":"OG000","value":"-1.25","spread":"0.07"},{"groupId":"OG001","value":"-1.49","spread":"0.06"}]}]},{"title":"Endpoint (LOCF) Change","categories":[{"measurements":[{"groupId":"OG000","value":"-1.21","spread":"0.07"},{"groupId":"OG001","value":"-1.43","spread":"0.07"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.003","pValueComment":"p-value is for 24 Weeks change.","statisticalMethod":"ANCOVA","statisticalComment":"Variable = Treatment + Baseline + Baseline HbA1c Group + Baseline SU Group","paramType":"Mean Difference (Final Values)","paramValue":"0.24","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.08","ciUpperLimit":"0.39"},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.008","pValueComment":"p-value is for Endpoint (LOCF) Change.","statisticalMethod":"ANCOVA","paramType":"Mean Difference (Final Values)","paramValue":"0.22","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.06","ciUpperLimit":"0.38"}]},{"type":"SECONDARY","title":"Percentage of Participants With Hemoglobin A1C Less Than 7.0% and Hemoglobin A1C Less Than or Equal to 6.5%","populationDescription":"All randomized participants with at least one post-baseline measurement. Intention to Treat (ITT) population.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percent of participants","timeFrame":"Weeks 12, 18, 24 and Endpoint (LOCF) up to 24 weeks","groups":[{"id":"OG000","title":"ILPS","description":"Insulin Lispro Protamine Suspension (ILPS) administered subcutaneously once a day at bedtime for 24 weeks"},{"id":"OG001","title":"Glargine","description":"Insulin Glargine administered subcutaneously once a day at bedtime for 24 weeks"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"170"},{"groupId":"OG001","value":"167"}]}],"classes":[{"title":"Week 12: HbA1c <7.0%","categories":[{"measurements":[{"groupId":"OG000","value":"46.9"},{"groupId":"OG001","value":"50.7"}]}]},{"title":"Week 12: HbA1c <=6.5%","categories":[{"measurements":[{"groupId":"OG000","value":"24.8"},{"groupId":"OG001","value":"28.7"}]}]},{"title":"Week 18: HbA1c <7.0%","categories":[{"measurements":[{"groupId":"OG000","value":"54.8"},{"groupId":"OG001","value":"69.1"}]}]},{"title":"Week 18: HbA1c <=6.5%","categories":[{"measurements":[{"groupId":"OG000","value":"30.8"},{"groupId":"OG001","value":"37.6"}]}]},{"title":"Week 24: HbA1c <7.0%","categories":[{"measurements":[{"groupId":"OG000","value":"55.4"},{"groupId":"OG001","value":"63.4"}]}]},{"title":"Week 24: HbA1c <=6.5%","categories":[{"measurements":[{"groupId":"OG000","value":"29.7"},{"groupId":"OG001","value":"39.9"}]}]},{"title":"Endpoint (LOCF): HbA1c <7.0%","categories":[{"measurements":[{"groupId":"OG000","value":"53.7"},{"groupId":"OG001","value":"61.7"}]}]},{"title":"Endpoint (LOCF): HbA1c <=6.5%","categories":[{"measurements":[{"groupId":"OG000","value":"28.4"},{"groupId":"OG001","value":"38.9"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.561","pValueComment":"p-value is for Week 12: HbA1c \\<7.0%","statisticalMethod":"Fisher Exact","ciPctValue":"95"},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.511","pValueComment":"p-value is for Week 12: HbA1c \\<=6.5%","statisticalMethod":"Fisher Exact","ciPctValue":"95"},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.012","pValueComment":"p-value is for Week 18: HbA1c \\<7.0%","statisticalMethod":"Fisher Exact","ciPctValue":"95"},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.269","pValueComment":"p-value is for Week 18: HbA1c \\<=6.5%","statisticalMethod":"Fisher Exact","ciPctValue":"95"},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.161","pValueComment":"p-value is for Week 24: HbA1c \\<7.0%","statisticalMethod":"Fisher Exact","ciPctValue":"95"},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.071","pValueComment":"p-value is for Week 24: HbA1c \\<=6.5%","statisticalMethod":"Fisher Exact","ciPctValue":"95"},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.177","pValueComment":"p-value is for Endpoint (LOCF): HbA1c \\<7.0%","statisticalMethod":"Fisher Exact","ciPctValue":"95"},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.060","pValueComment":"p-value is for Endpoint (LOCF): HbA1c \\<=6.5%","statisticalMethod":"Fisher Exact","ciPctValue":"95"}]},{"type":"SECONDARY","title":"7-Point Self-Monitored Blood Glucose (SMBG) Profiles at Baseline and Endpoint (LOCF)","description":"SMBG at morning pre-meal, morning post-prandial, midday pre-meal, midday post-prandial, evening pre-meal, evening postprandial, 0300 hours. Post-prandial glucose is measured 2 hours after the start of the meal.","populationDescription":"All randomized participants with at least one post-baseline measurement. Intention to Treat (ITT) population.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"milligrams per deciliter (mg/dL)","timeFrame":"Baseline, Endpoint (LOCF) up to 24 weeks","groups":[{"id":"OG000","title":"ILPS","description":"Insulin Lispro Protamine Suspension (ILPS) administered subcutaneously once a day at bedtime for 24 weeks"},{"id":"OG001","title":"Glargine","description":"Insulin Glargine administered subcutaneously once a day at bedtime for 24 weeks"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"170"},{"groupId":"OG001","value":"167"}]}],"classes":[{"title":"Baseline Morning Pre-Meal","categories":[{"measurements":[{"groupId":"OG000","value":"175.41","spread":"39.54"},{"groupId":"OG001","value":"180.86","spread":"38.95"}]}]},{"title":"Baseline Morning Postprandial","categories":[{"measurements":[{"groupId":"OG000","value":"195.31","spread":"54.65"},{"groupId":"OG001","value":"190.84","spread":"54.95"}]}]},{"title":"Baseline Midday Pre-Meal","categories":[{"measurements":[{"groupId":"OG000","value":"165.18","spread":"43.51"},{"groupId":"OG001","value":"166.34","spread":"47.64"}]}]},{"title":"Baseline Midday Postprandial","categories":[{"measurements":[{"groupId":"OG000","value":"193.22","spread":"46.95"},{"groupId":"OG001","value":"200.25","spread":"54.64"}]}]},{"title":"Baseline Evening Pre-Meal","categories":[{"measurements":[{"groupId":"OG000","value":"173.33","spread":"44.60"},{"groupId":"OG001","value":"175.14","spread":"43.35"}]}]},{"title":"Baseline Evening Postprandial","categories":[{"measurements":[{"groupId":"OG000","value":"189.00","spread":"49.62"},{"groupId":"OG001","value":"184.92","spread":"49.42"}]}]},{"title":"Baseline 0300 Hours","categories":[{"measurements":[{"groupId":"OG000","value":"170.51","spread":"43.44"},{"groupId":"OG001","value":"172.00","spread":"39.10"}]}]},{"title":"Baseline Daily Mean 7-Point Blood Glucose","categories":[{"measurements":[{"groupId":"OG000","value":"180.19","spread":"36.95"},{"groupId":"OG001","value":"180.72","spread":"38.17"}]}]},{"title":"Baseline Daily Mean Pre-Meal","categories":[{"measurements":[{"groupId":"OG000","value":"170.60","spread":"36.06"},{"groupId":"OG001","value":"172.66","spread":"38.60"}]}]},{"title":"Baseline Daily Mean Postprandial","categories":[{"measurements":[{"groupId":"OG000","value":"192.37","spread":"41.48"},{"groupId":"OG001","value":"191.27","spread":"46.11"}]}]},{"title":"Endpoint Morning Pre-Meal","categories":[{"measurements":[{"groupId":"OG000","value":"129.63","spread":"31.58"},{"groupId":"OG001","value":"127.01","spread":"29.08"}]}]},{"title":"Endpoint Morning Postprandial","categories":[{"measurements":[{"groupId":"OG000","value":"152.32","spread":"44.81"},{"groupId":"OG001","value":"137.39","spread":"36.65"}]}]},{"title":"Endpoint Midday Pre-Meal","categories":[{"measurements":[{"groupId":"OG000","value":"132.84","spread":"36.63"},{"groupId":"OG001","value":"129.71","spread":"34.34"}]}]},{"title":"Endpoint Midday Postprandial","categories":[{"measurements":[{"groupId":"OG000","value":"161.77","spread":"42.46"},{"groupId":"OG001","value":"155.26","spread":"37.86"}]}]},{"title":"Endpoint Evening Pre-Meal","categories":[{"measurements":[{"groupId":"OG000","value":"146.03","spread":"37.93"},{"groupId":"OG001","value":"135.93","spread":"33.79"}]}]},{"title":"Endpoint Evening Postprandial","categories":[{"measurements":[{"groupId":"OG000","value":"159.14","spread":"45.35"},{"groupId":"OG001","value":"144.25","spread":"34.17"}]}]},{"title":"Endpoint 0300 Hours","categories":[{"measurements":[{"groupId":"OG000","value":"123.96","spread":"35.45"},{"groupId":"OG001","value":"127.53","spread":"30.90"}]}]},{"title":"Endpoint Daily Mean 7-Point Blood Glucose","categories":[{"measurements":[{"groupId":"OG000","value":"143.06","spread":"30.00"},{"groupId":"OG001","value":"136.17","spread":"25.65"}]}]},{"title":"Endpoint Daily Mean Pre-Meal","categories":[{"measurements":[{"groupId":"OG000","value":"135.51","spread":"30.39"},{"groupId":"OG001","value":"129.32","spread":"26.54"}]}]},{"title":"Endpoint Daily Mean Postprandial","categories":[{"measurements":[{"groupId":"OG000","value":"158.10","spread":"36.81"},{"groupId":"OG001","value":"146.12","spread":"30.37"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.179","pValueComment":"p-value is for Endpoint Morning Pre-Meal.","statisticalMethod":"ANCOVA","statisticalComment":"Variable = Treatment + Baseline + Baseline HbA1c Group + Baseline SU Group","paramType":"Mean Difference (Final Values)","paramValue":"4.28","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-1.97","ciUpperLimit":"10.53"},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","pValueComment":"p-value is for Endpoint Morning Postprandial.","statisticalMethod":"ANCOVA","statisticalComment":"Variable = Treatment + Baseline + Baseline HbA1c Group + Baseline SU Group","paramType":"Mean Difference (Final Values)","paramValue":"13.96","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"5.72","ciUpperLimit":"22.19"},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.325","pValueComment":"p-value is for Endpoint Midday Pre-Meal.","statisticalMethod":"ANCOVA","statisticalComment":"Variable = Treatment + Baseline + Baseline HbA1c Group + Baseline SU Group","paramType":"Mean Difference (Final Values)","paramValue":"3.80","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-3.79","ciUpperLimit":"11.39"},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.051","pValueComment":"p-value is for Endpoint Midday Postprandial.","statisticalMethod":"ANCOVA","statisticalComment":"Variable = Treatment + Baseline + Baseline HbA1c Group + Baseline SU Group","paramType":"Mean Difference (Final Values)","paramValue":"8.73","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.04","ciUpperLimit":"17.50"},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.003","pValueComment":"p-value is for Endpoint Evening Pre-Meal.","statisticalMethod":"ANCOVA","statisticalComment":"Variable = Treatment + Baseline + Baseline HbA1c Group + Baseline SU Group","paramType":"Mean Difference (Final Values)","paramValue":"10.92","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"3.66","ciUpperLimit":"18.19"},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.002","pValueComment":"p-value is for Endpoint Evening Postprandial.","statisticalMethod":"ANCOVA","statisticalComment":"Variable = Treatment + Baseline + Baseline HbA1c Group + Baseline SU Group","paramType":"Mean Difference (Final Values)","paramValue":"14.19","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"5.44","ciUpperLimit":"22.94"},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.415","pValueComment":"p-value is for Endpoint 0300 Hours.","statisticalMethod":"ANCOVA","statisticalComment":"Variable = Treatment + Baseline + Baseline HbA1c Group + Baseline SU Group","paramType":"Mean Difference (Final Values)","paramValue":"-3.03","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-10.35","ciUpperLimit":"4.28"},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.015","pValueComment":"p-value is for Endpoint Daily Mean 7-Point Blood Glucose.","statisticalMethod":"ANCOVA","statisticalComment":"Variable = Treatment + Baseline + Baseline HbA1c Group + Baseline SU Group","paramType":"Mean Difference (Final Values)","paramValue":"7.39","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.46","ciUpperLimit":"13.32"},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.021","pValueComment":"p-value is for Endpoint Daily Mean Pre-Meal.","statisticalMethod":"ANCOVA","statisticalComment":"Variable = Treatment + Baseline + Baseline HbA1c Group + Baseline SU Group","paramType":"Mean Difference (Final Values)","paramValue":"7.12","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.10","ciUpperLimit":"13.14"},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","pValueComment":"p-value is for Endpoint Daily Mean Postprandial.","statisticalMethod":"ANCOVA","statisticalComment":"Variable = Treatment + Baseline + Baseline HbA1c Group + Baseline SU Group","paramType":"Mean Difference (Final Values)","paramValue":"11.97","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"5.01","ciUpperLimit":"18.93"}]},{"type":"SECONDARY","title":"Glycemic Variability at Baseline and Endpoint (LOCF)","description":"Glycemic variability was defined as the standard deviation (SD) of a participant's intra-day 7-point, self-monitored, blood glucose. Mean SD was calculated based on the SD for each participant in the study.","populationDescription":"All randomized participants with at least one post-baseline measurement. Intention to Treat (ITT) population.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"mg/dL","timeFrame":"Baseline, Endpoint (LOCF) up to 24 weeks","groups":[{"id":"OG000","title":"ILPS","description":"Insulin Lispro Protamine Suspension (ILPS) administered subcutaneously once a day at bedtime for 24 weeks"},{"id":"OG001","title":"Glargine","description":"Insulin Glargine administered subcutaneously once a day at bedtime for 24 weeks"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"170"},{"groupId":"OG001","value":"167"}]}],"classes":[{"title":"Baseline","categories":[{"measurements":[{"groupId":"OG000","value":"41.15","spread":"13.69"},{"groupId":"OG001","value":"39.02","spread":"13.52"}]}]},{"title":"Endpoint","categories":[{"measurements":[{"groupId":"OG000","value":"36.78","spread":"16.02"},{"groupId":"OG001","value":"30.96","spread":"13.24"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.131","pValueComment":"p-value is for Baseline.","statisticalMethod":"ANOVA","statisticalComment":"Variable = Treatment + Baseline HbA1c Group + Baseline SU Group","paramType":"Mean Difference (Final Values)","paramValue":"2.27","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.68","ciUpperLimit":"5.22"},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","pValueComment":"p-value is for Endpoint.","statisticalMethod":"ANOVA","statisticalComment":"Variable = Treatment + Baseline HbA1c Group + Baseline SU Group","paramType":"Mean Difference (Final Values)","paramValue":"5.99","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"2.82","ciUpperLimit":"9.16"}]},{"type":"SECONDARY","title":"Incidence of Self-reported Hypoglycemic Episodes (All, Non-Nocturnal, Nocturnal, and Severe)","description":"Overall:any time after randomization.Episode:any time patient experienced sign/symptom associated with hypoglycemia, or had blood glucose level ≤70 mg/dL. Non-nocturnal:any episode that occurred between waking and bedtime. Nocturnal:any episode that occurred between bedtime and waking.Severe:episode with symptoms consistent with neuroglycopenia in which patient requires assistance,and is associated with:blood glucose value \\<50 mg/dL or prompt recovery after oral carbohydrate, glucagon, or intravenous glucose.Incidence(%)=(Number of patients experiencing episodes/number of patients in arm)\\*100.","populationDescription":"All randomized participants with at least one post-baseline measurement. Intention to Treat (ITT) population.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Baseline to Endpoint (LOCF) up to 24 weeks","groups":[{"id":"OG000","title":"ILPS","description":"Insulin Lispro Protamine Suspension (ILPS) administered subcutaneously once a day at bedtime for 24 weeks"},{"id":"OG001","title":"Glargine","description":"Insulin Glargine administered subcutaneously once a day at bedtime for 24 weeks"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"170"},{"groupId":"OG001","value":"167"}]}],"classes":[{"title":"All Reported - Endpoint","categories":[{"measurements":[{"groupId":"OG000","value":"41.8"},{"groupId":"OG001","value":"43.1"}]}]},{"title":"All Reported - Overall","categories":[{"measurements":[{"groupId":"OG000","value":"70.6"},{"groupId":"OG001","value":"74.9"}]}]},{"title":"Non-Nocturnal - Endpoint","categories":[{"measurements":[{"groupId":"OG000","value":"30.6"},{"groupId":"OG001","value":"40.1"}]}]},{"title":"Non-Nocturnal - Overall","categories":[{"measurements":[{"groupId":"OG000","value":"62.4"},{"groupId":"OG001","value":"70.7"}]}]},{"title":"Nocturnal - Endpoint","categories":[{"measurements":[{"groupId":"OG000","value":"21.8"},{"groupId":"OG001","value":"11.4"}]}]},{"title":"Nocturnal - Overall","categories":[{"measurements":[{"groupId":"OG000","value":"47.6"},{"groupId":"OG001","value":"37.1"}]}]},{"title":"Severe - Endpoint","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Severe - Overall","categories":[{"measurements":[{"groupId":"OG000","value":"1.8"},{"groupId":"OG001","value":"0"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.826","pValueComment":"p-value is for all reported hypoglycemic events at endpoint.","statisticalMethod":"Fisher Exact","ciPctValue":"95"},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.394","pValueComment":"p-value is for all reported hypoglycemic events overall.","statisticalMethod":"Fisher Exact","ciPctValue":"95"},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.070","pValueComment":"p-value is for non-nocturnal hypoglycemic events at endpoint.","statisticalMethod":"Fisher Exact","ciPctValue":"95"},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.133","pValueComment":"p-value is for non-nocturnal hypoglycemic events overall.","statisticalMethod":"Fisher Exact","ciPctValue":"95"},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.013","pValueComment":"p-value is for nocturnal hypoglycemic events at endpoint.","statisticalMethod":"Fisher Exact","ciPctValue":"95"},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.061","pValueComment":"p-value is for nocturnal hypoglycemic events overall.","statisticalMethod":"Fisher Exact","ciPctValue":"95"},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.248","pValueComment":"p-value is for severe hypoglycemic events overall.","statisticalMethod":"Fisher Exact","ciPctValue":"95"}]},{"type":"SECONDARY","title":"Rate of All, Non-Nocturnal, and Nocturnal Self-Reported Hypoglycemic Episodes (Adjusted for One Year)","description":"Rate of self-reported hypoglycemic episodes, all, non-nocturnal, and nocturnal, at Endpoint (LOCF) and overall. Rate is reported as episodes/participant/365 days. Episode = any time participant feels that he/she is experiencing a sign or symptom that is associated with hypoglycemia or has a blood glucose level of ≤70 mg/dL, even if it was not associated with signs, symptoms, or treatment. Overall=any time during the post-randomization visits within the study period. Nocturnal=Any episode that occurs between bedtime and waking. Non-Nocturnal=Any episode that occurs between waking and bedtime.","populationDescription":"All randomized participants with at least one post-baseline measurement. Intention to Treat (ITT) population.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"episodes/participant/365 days","timeFrame":"Baseline to Endpoint (LOCF) up to 24 weeks","groups":[{"id":"OG000","title":"ILPS","description":"Insulin Lispro Protamine Suspension (ILPS) administered subcutaneously once a day at bedtime for 24 weeks"},{"id":"OG001","title":"Glargine","description":"Insulin Glargine administered subcutaneously once a day at bedtime for 24 weeks"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"170"},{"groupId":"OG001","value":"167"}]}],"classes":[{"title":"All reported episodes rate - Endpoint","categories":[{"measurements":[{"groupId":"OG000","value":"14.51","spread":"27.75"},{"groupId":"OG001","value":"15.29","spread":"29.73"}]}]},{"title":"All reported episodes rate - Overall","categories":[{"measurements":[{"groupId":"OG000","value":"16.27","spread":"23.19"},{"groupId":"OG001","value":"18.05","spread":"24.59"}]}]},{"title":"Non-Nocturnal reported episodes rate - Endpoint","categories":[{"measurements":[{"groupId":"OG000","value":"10.40","spread":"23.46"},{"groupId":"OG001","value":"13.20","spread":"28.01"}]}]},{"title":"Non-Nocturnal reported episodes rate - Overall","categories":[{"measurements":[{"groupId":"OG000","value":"11.36","spread":"19.16"},{"groupId":"OG001","value":"14.83","spread":"21.00"}]}]},{"title":"Nocturnal reported episodes rate - Endpoint","categories":[{"measurements":[{"groupId":"OG000","value":"4.01","spread":"9.73"},{"groupId":"OG001","value":"1.73","spread":"5.53"}]}]},{"title":"Nocturnal reported episodes rate - Overall","categories":[{"measurements":[{"groupId":"OG000","value":"4.88","spread":"8.43"},{"groupId":"OG001","value":"3.01","spread":"7.21"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.628","pValueComment":"p-value is for All reported episodes rate - Endpoint.","statisticalMethod":"Negative Binomial regression model","statisticalComment":"Total hypoglycemia count=Treatment+Baseline HbA1c Group+Baseline SU Group with log of patient's total number of days of exposure as an offset variable","ciPctValue":"95"},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.570","pValueComment":"p-value is for All reported episodes rate - Overall.","statisticalMethod":"Negative Binomial regression model","statisticalComment":"Total hypoglycemia count=Treatment+Baseline HbA1c Group+Baseline SU Group with log of patient's total number of days of exposure as an offset variable","ciPctValue":"95"},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.116","pValueComment":"p-value is for Non-Nocturnal reported episodes rate - Endpoint.","statisticalMethod":"Negative Binomial regression model","statisticalComment":"Total hypoglycemia count=Treatment+Baseline HbA1c Group+Baseline SU Group with log of patient's total number of days of exposure as an offset variable","ciPctValue":"95"},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.044","pValueComment":"p-value is for Non-Nocturnal reported episodes rate - Overall.","statisticalMethod":"Negative Binomial regression model","statisticalComment":"Total hypoglycemia count=Treatment+Baseline HbA1c Group+Baseline SU Group with log of patient's total number of days of exposure as an offset variable","ciPctValue":"95"},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.006","pValueComment":"p-value is for Nocturnal reported episodes rate - Endpoint.","statisticalMethod":"Negative Binomial regression model","statisticalComment":"Total hypoglycemia count=Treatment+Baseline HbA1c Group+Baseline SU Group with log of patient's total number of days of exposure as an offset variable","ciPctValue":"95"},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.004","pValueComment":"p-value is for Nocturnal reported episodes rate - Overall.","statisticalMethod":"Negative Binomial regression model","statisticalComment":"Total hypoglycemia count=Treatment+Baseline HbA1c Group+Baseline SU Group with log of patient's total number of days of exposure as an offset variable","ciPctValue":"95"}]},{"type":"SECONDARY","title":"Actual Body Weight at Baseline and Endpoint (LOCF)","populationDescription":"All randomized participants with at least one post-baseline measurement. Intention to Treat (ITT) population.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"kilograms","timeFrame":"Baseline, Endpoint (LOCF) up to 24 weeks","groups":[{"id":"OG000","title":"ILPS","description":"Insulin Lispro Protamine Suspension (ILPS) administered subcutaneously once a day at bedtime for 24 weeks"},{"id":"OG001","title":"Glargine","description":"Insulin Glargine administered subcutaneously once a day at bedtime for 24 weeks"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"170"},{"groupId":"OG001","value":"167"}]}],"classes":[{"title":"Baseline","categories":[{"measurements":[{"groupId":"OG000","value":"101.57","spread":"18.67"},{"groupId":"OG001","value":"102.62","spread":"19.58"}]}]},{"title":"Endpoint","categories":[{"measurements":[{"groupId":"OG000","value":"101.85","spread":"18.91"},{"groupId":"OG001","value":"103.28","spread":"19.42"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.343","pValueComment":"p-value is for endpoint.","statisticalMethod":"ANCOVA","statisticalComment":"Variable = Treatment + Baseline + Baseline HbA1c Group + Baseline SU Group (Type III sums of squares)","ciPctValue":"95"}]},{"type":"SECONDARY","title":"Change From Baseline in Body Weight at Endpoint (LOCF)","populationDescription":"All randomized participants with at least one post-baseline measurement. Intention to Treat (ITT) population.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"kilograms","timeFrame":"Baseline, Endpoint (LOCF) up to 24 weeks","groups":[{"id":"OG000","title":"ILPS","description":"Insulin Lispro Protamine Suspension (ILPS) administered subcutaneously once a day at bedtime for 24 weeks"},{"id":"OG001","title":"Glargine","description":"Insulin Glargine administered subcutaneously once a day at bedtime for 24 weeks"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"170"},{"groupId":"OG001","value":"167"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.27","spread":"3.38"},{"groupId":"OG001","value":"0.66","spread":"3.93"}]}]}],"analyses":[{"groupIds":["OG000"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.417","pValueComment":"p-value is for the change in body weight at endpoint in the ILPS treatment group.","statisticalMethod":"t-test, 2 sided","ciPctValue":"95"},{"groupIds":["OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.041","pValueComment":"p-value is for the change in body weight at endpoint in the glargine treatment group.","statisticalMethod":"t-test, 2 sided","ciPctValue":"95"},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.343","pValueComment":"p-value is for change in body weight at endpoint between ILPS and glargine treatment groups.","statisticalMethod":"ANOVA","paramType":"Mean Difference (Final Values)","paramValue":"-0.38","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-1.15","ciUpperLimit":"0.40"}]},{"type":"SECONDARY","title":"Total Daily Insulin Dose at Endpoint (LOCF)","populationDescription":"All randomized participants with at least one post-baseline measurement. Intention to Treat (ITT) population.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Units of Insulin","timeFrame":"Endpoint (LOCF) up to 24 weeks","groups":[{"id":"OG000","title":"ILPS","description":"Insulin Lispro Protamine Suspension (ILPS) administered subcutaneously once a day at bedtime for 24 weeks"},{"id":"OG001","title":"Glargine","description":"Insulin Glargine administered subcutaneously once a day at bedtime for 24 weeks"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"168"},{"groupId":"OG001","value":"165"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31.11","spread":"18.87"},{"groupId":"OG001","value":"37.93","spread":"18.46"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","statisticalMethod":"ANOVA","statisticalComment":"Variable = Treatment + Baseline HbA1c Group+ Baseline SU Group","ciPctValue":"95"}]}]},"adverseEventsModule":{"frequencyThreshold":"2","description":"Adverse events are reported for the Intention to Treat (ITT) population.","eventGroups":[{"id":"EG000","title":"ILPS","description":"Insulin Lispro Protamine Suspension (ILPS) administered subcutaneously once a day at bedtime for 24 weeks","seriousNumAffected":9,"seriousNumAtRisk":170,"otherNumAffected":96,"otherNumAtRisk":170},{"id":"EG001","title":"Glargine","description":"Insulin Glargine administered subcutaneously once a day at bedtime for 24 weeks","seriousNumAffected":5,"seriousNumAtRisk":167,"otherNumAffected":115,"otherNumAtRisk":167}],"seriousEvents":[{"term":"Atrial fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":170},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":167}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":170},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":167}]},{"term":"Cholelithiasis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":170},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":167}]},{"term":"Appendicitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":170},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":167}]},{"term":"Cystitis bacterial","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":170},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":167}]},{"term":"Pneumonia pneumococcal","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":170},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":167}]},{"term":"Ankle fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":170},{"groupId":"EG001","numEvents":3,"numAffected":1,"numAtRisk":167}]},{"term":"Drug exposure during pregnancy","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":170},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":167}]},{"term":"Fall","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":170},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":167}]},{"term":"Heat exhaustion","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":170},{"groupId":"EG001","numEvents":3,"numAffected":1,"numAtRisk":167}]},{"term":"Joint injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":170},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":167}]},{"term":"Hypoglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":170},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":167}]},{"term":"Colon cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":170},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":167}]},{"term":"Nephrolithiasis","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":170},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":167}]}],"otherEvents":[{"term":"Abdominal discomfort","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":6,"numAtRisk":170},{"groupId":"EG001","numEvents":5,"numAffected":4,"numAtRisk":167}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":17,"numAffected":11,"numAtRisk":170},{"groupId":"EG001","numEvents":31,"numAffected":12,"numAtRisk":167}]},{"term":"Dyspepsia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":170},{"groupId":"EG001","numEvents":14,"numAffected":4,"numAtRisk":167}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":37,"numAffected":13,"numAtRisk":170},{"groupId":"EG001","numEvents":14,"numAffected":10,"numAtRisk":167}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":6,"numAtRisk":170},{"groupId":"EG001","numEvents":11,"numAffected":8,"numAtRisk":167}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":170},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":167}]},{"term":"Bronchitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":1,"numAtRisk":170},{"groupId":"EG001","numEvents":9,"numAffected":5,"numAtRisk":167}]},{"term":"Gastroenteritis viral","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":170},{"groupId":"EG001","numEvents":15,"numAffected":12,"numAtRisk":167}]},{"term":"Influenza","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":4,"numAtRisk":170},{"groupId":"EG001","numEvents":4,"numAffected":3,"numAtRisk":167}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":18,"numAffected":12,"numAtRisk":170},{"groupId":"EG001","numEvents":14,"numAffected":9,"numAtRisk":167}]},{"term":"Sinusitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":17,"numAffected":7,"numAtRisk":170},{"groupId":"EG001","numEvents":26,"numAffected":9,"numAtRisk":167}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":23,"numAffected":11,"numAtRisk":170},{"groupId":"EG001","numEvents":24,"numAffected":10,"numAtRisk":167}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":5,"numAtRisk":170},{"groupId":"EG001","numEvents":3,"numAffected":2,"numAtRisk":167}]},{"term":"Joint sprain","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":27,"numAffected":4,"numAtRisk":170},{"groupId":"EG001","numEvents":10,"numAffected":2,"numAtRisk":167}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":19,"numAffected":9,"numAtRisk":170},{"groupId":"EG001","numEvents":35,"numAffected":7,"numAtRisk":167}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":3,"numAtRisk":170},{"groupId":"EG001","numEvents":9,"numAffected":4,"numAtRisk":167}]},{"term":"Musculoskeletal pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":2,"numAtRisk":170},{"groupId":"EG001","numEvents":28,"numAffected":4,"numAtRisk":167}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":170},{"groupId":"EG001","numEvents":5,"numAffected":4,"numAtRisk":167}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":3,"numAtRisk":170},{"groupId":"EG001","numEvents":17,"numAffected":5,"numAtRisk":167}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":44,"numAffected":11,"numAtRisk":170},{"groupId":"EG001","numEvents":42,"numAffected":15,"numAtRisk":167}]},{"term":"Sinus headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":170},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":167}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":13,"numAffected":5,"numAtRisk":170},{"groupId":"EG001","numEvents":13,"numAffected":5,"numAtRisk":167}]},{"term":"Nasal congestion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":3,"numAtRisk":170},{"groupId":"EG001","numEvents":18,"numAffected":9,"numAtRisk":167}]},{"term":"Oropharyngeal pain","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":4,"numAtRisk":170},{"groupId":"EG001","numEvents":11,"numAffected":7,"numAtRisk":167}]},{"term":"Sinus congestion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":13,"numAffected":6,"numAtRisk":170},{"groupId":"EG001","numEvents":8,"numAffected":2,"numAtRisk":167}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"GT60","restrictiveAgreement":true},"pointOfContact":{"title":"Chief Medical Officer","organization":"Eli Lilly and Company","phone":"800-545-5979"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-10-09"},"conditionBrowseModule":{"meshes":[{"id":"D003924","term":"Diabetes Mellitus, Type 2"}],"ancestors":[{"id":"D003920","term":"Diabetes Mellitus"},{"id":"D044882","term":"Glucose Metabolism Disorders"},{"id":"D008659","term":"Metabolic Diseases"},{"id":"D009750","term":"Nutritional and Metabolic Diseases"},{"id":"D004700","term":"Endocrine System Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000069036","term":"Insulin Glargine"}],"ancestors":[{"id":"D049528","term":"Insulin, Long-Acting"},{"id":"D061385","term":"Insulins"},{"id":"D010187","term":"Pancreatic Hormones"},{"id":"D036361","term":"Peptide Hormones"},{"id":"D006728","term":"Hormones"},{"id":"D006730","term":"Hormones, Hormone Substitutes, and Hormone Antagonists"},{"id":"D010455","term":"Peptides"},{"id":"D000602","term":"Amino Acids, Peptides, and Proteins"}]}},"hasResults":true}